Published in final edited form as:

J Acquir Immune Defic Syndr. 2014 March 1; 65(3): 345–349. doi:10.1097/QAI.0000000000000073.

Pilot Study of Pioglitazone Prior to HCV Re-treatment in HIV/HCV Genotype 1-Infected Subjects with Insulin Resistance and Prior Nonresponse to Peginterferon and Ribavirin Therapy: A5239

Kristen Marks^{1,*}, Douglas Kitch², Raymond T. Chung³, Colleen Hadigan⁴, Janet Andersen², Phyllis Tien⁵, Annie Luetkemeyer⁶, Beverly Alston-Smith⁴, Marshall J. Glesby¹, and the A5239 team

¹Division of Infectious Diseases, Weill Cornell Medical College, New York, NY

²Harvard School of Public Health, Boston, MA

³GI Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA

⁴National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

⁵Division of Infectious Diseases, University of California San Francisco Medical School, San Francisco, CA, and Medical Service, Department of Veterans Affairs, San Francisco, CA

⁶HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA.

Abstract

Insulin resistance (IR) is associated with nonresponse to HCV treatment. In this multicenter, single-arm pilot study, adult, HIV/HCV genotype 1 coinfecting prior nonresponders to peginterferon/ribavirin (PegIFN/RBV) with homeostatic model assessment-IR >2.5 were treated with pioglitazone (PIO) for 24 weeks followed by PegIFN/RBV/PIO. 3/19 subjects (15.8%) achieved undetectable HCV RNA at week 24 of PegIFN/RBV/PIO which was not significantly different than the historical null rate of 10% ($p=0.29$, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, ALT and AST declined significantly and correlated with improved metabolic parameters.

Keywords

hepatitis C; HIV; insulin resistance; pegylated interferon; nonresponder; metabolic

Introduction

Insulin resistance and its associated condition, fatty liver, occur commonly in HIV/HCV coinfecting patients¹⁻¹⁰ and are associated with up to 50% poorer response rates to pegylated interferon alfa and ribavirin (PegIFN/RBV) treatment^{1;11}. Mechanisms by which HCV

*Corresponding author: 525 East 68th Street, F24, New York, NY, 10065, phone 212-746-4177, fax 212-746-8852, markskr@med.cornell.edu.

These data were presented in part at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Mar 5-8, 2012.

Clinical trials registration number: NCT00665353

contributes to insulin resistance include both direct effects of viral proteins on insulin signaling and indirect effects of HCV-induced proinflammatory cytokines¹². Pioglitazone (PIO) targets the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) receptor that controls the expression of insulin-sensitizing genes. Because the intracellular signaling pathways for insulin and interferon signaling overlap, it is plausible that improving insulin sensitivity could improve interferon responsiveness¹². For these reasons, we hypothesized that treating insulin resistance with pioglitazone would improve virologic response rates to PegIFN/RBV retreatment. We also examined for beneficial effects of PIO monotherapy on liver and metabolic parameters.

Methods

Study Design

A5239 was a single-arm pilot study in which prior nonresponders to PegIFN/RBV with documented insulin resistance were treated with PIO prior to and during hepatitis C retreatment. Subjects received 24 weeks of PIO followed by continued PIO therapy plus PegIFN/RBV for 12-48 weeks depending on treatment response. The primary endpoint of the study was virologic response defined as HCV RNA below the limit of quantitative assay detection at week 24 of PegIFN/RBV/PIO treatment. This was chosen as the primary endpoint because neither null nor partial responders would have achieved this endpoint during their prior HCV treatment course. Subjects were also evaluated for sustained virologic response (SVR) 24 weeks after completion of PegIFN/RBV/PIO.

Eligibility Criteria

The study population was HIV-1/HCV genotype 1-infected adults with insulin resistance and non-response to previous treatment with PegIFN alfa-2a 180 mcg/week, or alfa-2b 1.5 mcg/kg/week, and 1000 mg/day RBV given for at least 12 consecutive weeks. Prior nonresponse status was defined as: prior null responder with $<2 \log_{10}$ drop in HCV RNA from pretreatment levels AND detectable HCV RNA by RT-PCR or bDNA assay after 10 weeks and <22 weeks of therapy OR prior partial responder with detectable HCV RNA by RT-PCR or bDNA assay after 22 weeks and <30 weeks of therapy, not attributable to nonadherence or dose reductions. Relapsers were excluded. Insulin resistance was defined as homeostatic model assessment of insulin resistance (HOMA-IR) value of >2.5 (calculated as fasting serum insulin ($\mu\text{U/mL}$) $\times$ fasting plasma glucose (mg/dL)/405), consistent with many other studies of insulin resistance and HCV treatment^{1;2;11;13-15}. Subjects with diabetes, fasting plasma glucose $\geq 126 \text{ mg/dL}$, or on antidiabetic medications were excluded.

Subjects were required to have CD4^+ cell counts $\geq 200 \text{ cells}/\mu\text{L}$, no active opportunistic infections, no antiretroviral therapy (ART) or stable ART that did not include zidovudine or didanosine for at least 12 weeks prior to study entry. Subjects with renal insufficiency, significant anemia, decompensated cirrhosis, chronic hepatitis B, other liver disease (besides nonalcoholic fatty liver disease), or other contraindications to treatment with peginterferon/ribavirin were excluded.

Informed consent was obtained from subjects. Human experimentation guidelines of the United States Department of Health and Human Services and those of the study sites' institutions were followed in the conduct of this study.

Study Treatment

All subjects received at least 24 weeks of PIO 30 mg/day prior to PegIFN/RBV. Management for hepatotoxicity was prespecified based on elevations in transaminases, bilirubin, or signs of hepatic decompensation. PegIFN alfa-2a (Pegasys™; Roche (Genentech)) was dosed at 180 mcg/week. Ribavirin (Copegus™; Roche(Genentech)) dose was weight-based, with doses of 1000(<75 kg) or 1200mg/day(≥75 kg) divided twice daily. PegIFN and RBV doses were reduced if prespecified toxicity criteria were met. Dose escalation was permitted if toxicities resolved. Concurrent use of growth factors was permitted for neutropenia and anemia. Stopping rules for treatment futility were applied including <2 log₁₀ drop in HCV RNA after 12 weeks or detectable HCV RNA after 24 weeks of PegIFN/RBV/PIO.

Study Evaluations

Subjects were evaluated for adverse events and safety laboratory tests (including hepatic function panels) during PIO monotherapy (Weeks 2, 4, 8, 12, 18, 24) and during PegIFN/RBV/PIO (weeks 2, 4, 8, 12, 16, 24, 32, 40, 48). HCV viremia was assessed at a central lab by quantitative real-time PCR (Roche COBAS Amplicor v 2.0) at entry, PIO week 24, and PIO/PegIFN/RBV weeks 4, 12, 24, 48, 72 (lower level of quantification was 43 IU/mL). Fasting insulin, glucose, leptin, adiponectin, and cholesterol levels were performed at entry, PIO weeks 12, 24, and PIO/PegIFN/RBV weeks 12, 24, 48, 72. Oral glucose tolerance tests (OGTT) were performed at entry and PIO week 24. All metabolic testing aside from routine fasting glucose levels was performed centrally on stored specimens (Quest Diagnostics, Baltimore, MD): adiponectin by ELISA with coefficient of variation (CV) 3.3-7.3%(B-Bridge International, Sunnyvale, CA), insulin by enzyme-based chemiluminescent immunometric assay with CV 3.7%-7.3% (Siemens Healthcare Diagnostics, Deerfield, IL), leptin by electrochemiluminescence with CV 7.8%-12.0% (Nichols Institute, San Juan Capistrano, CA).

Statistical Methods

The primary endpoint was virologic response defined as undetectable HCV RNA at week 24 of PIO/PegIFN/RBV treatment. Secondary endpoints included SVR, safety endpoints, and changes in metabolic parameters and transaminase levels during PIO monotherapy.

The study was powered to detect a week 24 response rate of at least 30% which was the minimum response felt to be meaningful in terms of further pursuing this strategy. Based on this response rate and using a one-sided type I error of 10%, a sample size of 30 subjects allowed 90% power to detect a significant increase from a historical null rate (at week 24 of retreatment) of 10%. The relaxed type I error of 10% was used to allow for high power for detection of a positive effect with the plan to confirm a positive finding with a larger study.

All analyses were conducted as intent-to-treat. For virologic response rates, an exact test of proportions (and corresponding lower limit of the one-sided 90% CI) was used. For change in continuous endpoints, a two-sided Wilcoxon signed rank test was used to assess if the changes were significantly different than zero. P-values <0.10 were deemed statistically significant, and nominal values are reported without adjustment for multiple comparisons. Analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, NC) and StatXact, version 9.0 (Cytel Inc., Cambridge, MA).

Results

The study accrued 19 of the planned 30 subjects between March 2009 and November 2010 before being closed due to slow accrual. The majority of the 31 subjects who failed screening were excluded for HOMA-IR ≥ 2.5 . Of enrolled subjects, 84% were male, 47% were black non-Hispanic, 11% were Hispanic and 42% were white non-Hispanic. Thirteen were prior null responders while 6 were partial responders. All but one participant was on ART (10 were on protease inhibitor-based and 8 NNRTI-based regimens; no regimens included stavudine), median CD4 was 532 cells/ μ L and 79% had HIV RNA <50 copies/ml. Their median BMI was 27.7, median HOMA-IR was 4.5, and 89% had HCV RNA levels $\leq 1,000,000$ IU/mL.

HCV Virologic Responses

Of the 19 subjects, 3 (15.8 %) achieved undetectable HCV RNA at week 24 of PIO/PegIFN/RBV, which did not differ significantly from the historical null rate of 10% ($p=0.29$, lower limit of the exact 1-sided 90% CI = 5.9%). Of the 3 subjects who were below detection at week 24, 1 had virologic relapse post treatment, 1 was lost to follow up, and 1 subject had an SVR. Of the other 16 subjects, 3 discontinued during PIO monotherapy (1 abnormal liver tests, 2 other reasons), 1 was lost to follow up, and 12 met the study defined criteria for virologic nonresponse at week 12 (10 subjects) or 24 (2 subjects).

Safety

Grade 3 ALT elevations were reported in 3 subjects during PIO monotherapy. PIO was continued in one, held in one, and discontinued in the other. There were no reports of hepatic decompensation. Two other grade 3 adverse events (lipase and phosphorus) and two Grade 4 events (lipase and neutropenia) occurred during PIO monotherapy. There was a slight decline in hemoglobin levels (median decrease 0.3 g/dL, $p=0.14$) and increase in weight (median increase 1.6 kg, $p=0.21$) during PIO monotherapy.

Effects of PIO monotherapy

Over the 24 weeks of PIO monotherapy, statistically significant declines in ALT and AST occurred (Figure 1). No significant changes in HCV RNA, bilirubin or GGT were observed. Table 1 shows metabolic outcomes of PIO monotherapy. Statistically significant increases in adiponectin and decreases in fasting insulin, HOMA-IR, and glucose area under the curve during OGTT were observed. Leptin and cholesterol levels did not change significantly. The decline in ALT correlated with change in HOMA-IR (Spearman's $r = 0.609$, $p = 0.012$), fasting glucose ($r=0.521$, $p=0.038$), fasting insulin ($r=0.624$, $p=0.010$), and insulin AUC

($r=0.610$, $p=0.027$). The decline in AST correlated with change in leptin and fasting glucose levels ($r=0.492$, $p=0.053$ and $r=0.563$, $p=0.023$, respectively).

Discussion

Despite recent advances in HCV therapy, the treatment of prior PegIFN/RBV nonresponders remains challenging. Given the association between insulin resistance (IR) and nonresponse to HCV treatment, we hypothesized that PIO would enhance interferon responsiveness and improve virologic response rates during PegIFN/RBV retreatment of HCV in HIV-infected subjects with IR. After pretreatment with PIO, 3 of 19 subjects achieved undetectable HCV RNA at week 24 of PegIFN/RBV/PIO, of which, only 1 achieved an SVR. Thus, there was no signal to suggest that PIO enhanced treatment response rates in this patient population.

Others have examined whether targeting insulin resistance improves HCV treatment outcomes in HIV-uninfected persons with both positive^{13;16} and negative results^{14;15;17}. The only other such published study of nonresponders, a single arm, multicenter study designed to look at PIO given simultaneously with initiation of HCV retreatment, was terminated early after the first 5 subjects had unsatisfactory virologic responses at week 12¹⁵. Notably, that study dosed PIO at only 15 mg daily, and 2 of the 5 subjects demonstrated worsened IR at week 12. More data exist regarding the use of this strategy in HCV treatment-naïve populations. Two prospective randomized, controlled studies investigated the addition of PIO to PegIFN/RBV therapy in HIV-uninfected, HCV-infected patients undergoing their initial course of PegIFN/RBV. The first included HCV genotype 4 subjects and demonstrated improved on-treatment response and SVR rates in patients randomized to PIO compared to placebo (rapid virologic response 27% vs. 6% and SVR 60% vs. 39%, respectively)¹⁶. In the other study which included subjects with HCV genotype 1, PIO improved IR but did not improve on-treatment response or SVR rates (SVR 41% PIO vs. 57% no PIO)¹⁴. Both studies used PIO doses of at least 30 mg, however PIO was started concurrently with HCV therapy in the study of genotype 4 subjects and 16 weeks prior to HCV treatment in the genotype 1 study. Differences in regimen (e.g. insulin-sensitizing agent, dosage, simultaneous versus insulin-sensitizing agent first), definition of insulin resistance, HCV genotype, study population (e.g. HCV treatment experience status), and efficacy of improving IR may account for the variability of responses in these and other studies.

Our study had several important limitations, including its single arm design, small sample size and under enrollment. Nonetheless, while we did not show improvement in virologic response, we did show a significant improvement in serum aminotransferase levels during PIO monotherapy that correlated with improvements in metabolic parameters. Given that HCV RNA levels did not decline during PIO monotherapy, the improvement in AST and ALT levels may relate to reduced necroinflammation in the liver, such as that described in studies of PIO for nonalcoholic steatohepatitis (NASH) treatment^{18;19}. While histopathologic evaluation of the liver was not performed in this study, past studies of PIO for NASH have demonstrated histologic improvement including reduced steatosis as well lobular inflammation and ballooning necrosis^{18;19}. In addition to improved histology and aminotransferase levels, these studies of NASH also showed improvements in metabolic

parameters such as HOMA-IR and adiponectin levels, similar to what we observed. Our study is the first to demonstrate this effect of PIO in improving laboratory markers of liver necroinflammation in HIV-infected individuals with HCV and IR. While safety considerations have emerged for thiazolidinediones like PIO, selective PPAR-gamma modulators in development with potentially superior safety profiles beckon future study of this finding.

In summary, treating insulin resistance with PIO prior to and during HCV retreatment in prior nonresponders did not produce a week 24 response or SVR rate sufficient to justify using this approach routinely but has not ruled out its potential utility in select populations. Decreases in serum aminotransferase levels and improvements in metabolic parameters were observed during PIO monotherapy. Since insulin resistance and fatty liver occur commonly in both HIV/HCV coinfecting and HIV-monoinfecting patients, therapies targeting PPAR-gamma or other strategies for improving insulin sensitivity warrant further investigation.

Acknowledgments

We thank the study participants and their families and caregivers for participation in the trial. In addition to the authors, the A5239 study team included: Atul Bahn, Travis Behm, Dawn Bozzolo, Joan Dragavon, Selin Hall, Valery Hughes, Anne Kmack, Holly Meyers, Orlando Roman, Katherine Shin, Jennifer Tiu, John Whitbread, and Louis Zimmerman. We also acknowledge Bill Meyer of Quest Diagnostics for his expertise in metabolic testing.

We acknowledge the participating ACTG study sites including particular individuals and relevant grant funding:

Valery Hughes, FNP and Christina Megill, PA-C- Cornell (Site 7804) CTU Grant U01 AI69419; Weill Cornell Medical College Clinical and Translational Science Center Grant UL1 TR000457.

Annie Luetkemeyer, MD and Jay Dwyer, RN- UCSF AIDS CRS (Site 801) CTU Grant 5U01 AI069502-07.

Karen Cavanagh, RN and Judith A. Aberg, MD- New York University/NYC HHC at Bellevue Hospital Center (Site 401) CTU Grant UM1AI069532.

Christine Hurley AIDS Care (site 1108) and Mary Adams- University of Rochester (Site 1101) CTU Grant UM1 AI069511.

Shobha Swaminathan, MD and Christie Lyn Costanza, BA- New Jersey Medical School (Site 31477).

Dr. Robert Kalayjian and Ann Marie Anderson, RN- MetroHealth Medical Center (Site 2503) CTU Grant AI69501; Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research. Some study data were collected and managed using REDCap electronic data capture tools hosted at MetroHealth Medical Center.

Donna McGregor, NP and Richard Green, MD- Northwestern University (A2701) CTU Grant AI 069471.

Richard Sterling MD, MSc and Vicky Watson, RN- Virginia Commonwealth University (Site 31475) CTU Grant 5-UM1-AI069503; CTSA award No. UL1TR000058 from the National Center for Advancing Translational Sciences.

Teri Flynn, ANP-BC and Amy Sbrolla, RN- Massachusetts General Hospital (Site 101) CTU Grant IU0IAI69472.

Potential conflict of interest

RC received research funding from Roche Labs. AFL has received research grant support to UCSF from Bristol-Myers Squibb, Gilead, and Vertex Pharmaceuticals. MJG has received research support from Pfizer to Weill Cornell Medical College and has served as a consultant to Gilead Sciences, SIGA Technologies, and Pfizer. KMM has received research support to Weill Cornell Medical College from Bristol-Myers Squibb, Vertex Pharmaceuticals, Janssen Pharmaceuticals, Boehringer Ingelheim, Gilead, and has received honoraria for lectures from Boehringer Ingelheim and Bristol-Myers Squibb.

Funding

The project described was supported by Award Number UM1AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. This research was also supported by Roche (Genentech) and Takeda Pharmaceuticals, U.S.A., Inc. Other grant support included 1 UM1 AI068634 and 5 U01 AI38855 to AACTG/ACTG Statistical and Data Management Center (SDMC); Intramural NIAID support (CH); NIH DK078772 (RC); K24 AI078884(MG), U01 AI069502 (AL).

Supported in part by CTU grants including U01 AI69419 (Cornell (Site 7804)), 5U01 AI069502-07(UCSF AIDS CRS (Site 801)), UM1AI069532 (New York University/NYC HHC at Bellevue Hospital Center (Site 401)), UM1 AI069511 (University of Rochester (Site 1101)), AI69501 (MetroHealth Medical Center (Site 2503)), AI 069471 (Northwestern University (A2701)), UM1-AI069503 (Virginia Commonwealth University (Site 31475)).

Supported in part by grants funded by site CTSCs including UL1 TR000457 (Cornell CTSC), UL1TR000439 (Clinical and Translational Science Collaborative of Cleveland), UL1TR000058 (Virginia Commonwealth University).

Reference List

1. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Pol S, Halfon P. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. *Antivir Ther.* 2009; 14:839–45. [PubMed: 19812446]
2. Donato C, Cingolani A, Pinnetti C, De LA. Insulin resistance and HCV virologic response to peginterferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. *J Hepatol.* 2010; 52:306–7. [PubMed: 20006404]
3. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2001; 27:245–50. [PubMed: 11464143]
4. Howard AA, Lo Y, Floris-Moore M, Klein RS, Fleischer N, Schoenbaum EE. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. *AIDS.* 2007; 21:633–41. [PubMed: 17314526]
5. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C mono-infection. *Hepatology.* 2005; 42:310–316. [PubMed: 16025515]
6. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfecting with HIV and hepatitis C virus. *AIDS.* 2005; 19:585–92. [PubMed: 15802977]
7. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfecting with HIV and hepatitis C virus. *Gastroenterology.* 2011; 140:809–17. [PubMed: 21134375]
8. Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miallhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E. Hepatic steatosis in HIV-HCV coinfecting patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. *BMC Res Notes.* 2012; 5:180. [PubMed: 22490728]
9. Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfecting persons: the AIDS Clinical Trials Group A5178 Study. *Clin Infect Dis.* 2012; 55:631–38. [PubMed: 22563020]
10. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfecting with HIV and hepatitis C virus. *J Infect Dis.* 2005; 192:1943–49. [PubMed: 16267765]
11. Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Brau N, Sterling RK, Slim J, Talal AH, Dieterich DT, Sulkowski MS. Insulin resistance predicts re-treatment failure in an

- efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. *J Hepatol.* 2011; 54:41–47. [PubMed: 20974502]
12. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? *J Hepatol.* 2012; 56(Suppl 1):S56–S65.
 13. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. *Int J Infect Dis.* 2012; 16:e436–e441. [PubMed: 22486858]
 14. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. *Hepatology.* 2012; 56:464–73. [PubMed: 22334369]
 15. Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. *J Hepatol.* 2008; 49:295–98. [PubMed: 18555553]
 16. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *Am J Gastroenterol.* 2010; 105:1970–1977. [PubMed: 20234345]
 17. Romero-Gomez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM, Sola R, Garcia-Samaniego J, Herrerias JM, De la MM, Moreno-Otero R, Nunez O, Olveira A, Duran S, Planas R. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology.* 2009; 50:1702–8. [PubMed: 19845037]
 18. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med.* 2006; 355:2297–307. [PubMed: 17135584]
 19. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van NM, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med.* 2010; 362:1675–85. [PubMed: 20427778]

Figure 1.

Change in Transaminase Levels during Pioglitazone Monotherapy; Median (Q1,Q3) Legend: Statistically significant declines in ALT and AST (expressed as absolute values (top boxes) and a ratio to the upper limit of normal (ULN) (bottom boxes)) occurred after the 24 week course of pioglitazone monotherapy. The statistical analysis was conducted using the ratio to ULN, since these were run at local labs with varying normal ranges [median (Q1,Q3) $-0.14 (-0.47, 0.02) \times \text{ULN}$ ($p=0.031$) and $-0.20 (-0.29, -0.08) \times \text{ULN}$ ($p=0.018$), respectively].

Table 1

Change in Hemoglobin, Liver-Related Tests and Metabolic Tests Observed During Pioglitazone Monotherapy

N=19 ^a	Baseline median (Q1,Q3)	Change during PIO median (Q1,Q3)	P value
Hemoglobin (g/dL)	14.3 (11.6,16.7)	-0.30 (-0.7,0)	0.140
ALT (U/L)	58 (43,74)	-9 (-19,1)	
($\times$ ULN) ^b	1.15 (0.92,1.37)	-0.14 (-0.47, 0.02)	0.031
AST (U/L)	50 (44,60)	-7 (-12, -3)	
($\times$ ULN) ^b	1.24 (1.09,1.51)	-0.20 (-0.29,-0.08)	0.018
GGT (IU/L)	130 (52,247)	-20 (-67,14)	0.46
HCV RNA (log ₁₀ IU/ml)	6.67 (6.46,6.92)	0.20 (-0.09,0.35)	0.17
Fasting Glucose (mg/dL)	106 (94,113)	-5.5 (-8,2.5)	0.19
Fasting Insulin (uIU/ml)^c	18.5 (13.5,26)	-5.5 (-14.5,4.5)	0.073
Glucose AUC (mg/dL/min)	136 (122,177)	-7.3 (-11.8,4.5)	0.095
Insulin AUC (uIU/ml/min) ^c	91 (58,144)	-26 (-73,17)	0.20
HOMA-IR^c	4.5 (3,6)	-1.4 (-4.1,0.9)	0.055
Total cholesterol (mg/dL)	153 (118,178)	5.5 (-2.0,20.5)	0.27
HDL cholesterol (mg/dL)	34 (23,102)	1.5 (-2.5,5.5)	0.45
Triglycerides (mg/dL)	161 (50,350)	28.5 (-15.5,73.0)	0.11
Adiponectin (ng/mL)	5 (3,9)	4.5 (2,8)	<0.001
Leptin (ng/mL)	7.3 (2.8,11.2)	-0.4 (-1.1,0.5)	0.30
Weight (kg)	83.7 (70.8,98.8)	1.6 (-0.5,2.5)	0.21

^a Number of subjects with available results (Week 0, Week 24): hemoglobin (19,17), ALT (19,19), AST (19,17), GGT (14,11), HCV RNA (19,17) fasting glucose (19,16), glucose AUC (18,16), fasting insulin (19,15), insulin AUC (18,13), HOMA-IR (19,15), cholesterol, triglycerides, adiponectin, leptin and weight (18,16).

^b ALT and AST were expressed as a ratio to the upper limit for statistical analyses since these were run at local labs with varying normal ranges.

^c Fasting insulin levels >300 uIU/ml (the upper limit) were interpreted as 300. One subject had a week 24 fasting insulin level considered to not be consistent with fasting. This measurement was excluded in the analyses shown here.